FDA Advisory Panel Votes to Permit Production of Controversial Peptide Drugs

During a two-day meeting of the Food and Drug Administration’s advisory committee, panelists voted on Thursday to allow specialized pharmacies to produce and sell seven peptide products that the agency banned three years earlier over safety concerns. The votes were non-binding but signaled a clear rebuke of FDA scientists who argued that the risks and benefits of the treatments had not been sufficiently studied. Additional votes on three more peptides are scheduled for Friday.

New York Times

Health Secretary Robert F. Kennedy Jr., who oversees the FDA, has long advocated for loosening restrictions on peptide therapies. In the weeks preceding the hearing, his office added eight new members to the advisory committee, six of whom have previously sold peptide products—some of which were banned—making health claims with minimal scientific backing. The peptides in question are primarily injectable “research-grade” products marketed online for claims ranging from tendon repair to brain health, despite the agency’s earlier ban.

New York Times

FDA scientists publicly expressed that the peptide drugs under review lacked adequate study of their safety and efficacy. The agency’s position, conveyed through its scientific staff, emphasized the need for rigorous clinical data before any broader distribution. Conversely, the Health Secretary’s office has signaled support for expanding access, framing the move as a step toward greater therapeutic options for patients.

New York Times

Consumer-health advocate Dr. Peter Lurie, president of the Center for Science in the Public Interest, condemned the panel’s actions.

New York Times

“I think we have seen an extraordinary abuse of the advisory committee process to secure ends that have no basis in science,” — Dr. Peter Lurie, president of the Center for Science in the Public Interest

New York Times

• Four peptide products received approval to be produced by specialized pharmacies on the first day of the meeting.

New York Times

• Votes on three additional peptides are slated for the following day.

New York Times

• The advisory committee’s recent expansion added eight members, six of whom have commercial ties to peptide sales.

New York Times